



NEWSLETTER

ILTOO Pharma joins the Global Day of Recognition of ALS/MND

Paris, 21 June 2023

Today, we come together to raise awareness and show solidarity for a cause that knows no borders - Amyotrophic Lateral Sclerosis (ALS)/ Motor Neurone Disease (MND). This devastating disease affects individuals in every corner of the world, regardless of nationality, race, or background.

ALS/MND is an unforgiving condition that progressively weakens the body's muscles, resulting in difficulties in movement, speech, and ultimately, the ability to breathe. It not only impacts the individuals diagnosed but also their families, friends, and communities. The challenges faced by those living with ALS/MND are immense, but their courage and resilience inspire us all.

ILTOO Pharma is actively engaged in the fight against ALS/MND. One of our key objectives is to make ILT-101, our lead drug, accessible to patients worldwide. ILT-101 has been specifically formulated to be easy to use and more suitable for long-term treatment, addressing the needs of patients in a comprehensive manner.

Our dedicated team at ILTOO Pharma has worked tirelessly to develop a ready-to-use formulation of ILT-101 which is designed to better fit the specific needs of ALS patients.

ILTOO Pharma remains committed to advancing research, collaborating with experts, and working closely with regulatory authorities to expedite the availability of ILT-101.

Let's stand together, united in our determination to ensure access to treatments and improve quality of life for individuals living with ALS/MND worldwide.

#ALSMNDWithoutBorders

<http://www.iltoopharma.com>